Literature DB >> 21161261

EEG low-resolution brain electromagnetic tomography (LORETA) in Huntington's disease.

Annamaria Painold1, Peter Anderer, Anna K Holl, Martin Letmaier, Gerda M Saletu-Zyhlarz, Bernd Saletu, Raphael M Bonelli.   

Abstract

Previous studies have shown abnormal electroencephalography (EEG) in Huntington's disease (HD). The aim of the present investigation was to compare quantitatively analyzed EEGs of HD patients and controls by means of low-resolution brain electromagnetic tomography (LORETA). Further aims were to delineate the sensitivity and utility of EEG LORETA in the progression of HD, and to correlate parameters of cognitive and motor impairment with neurophysiological variables. In 55 HD patients and 55 controls a 3-min vigilance-controlled EEG (V-EEG) was recorded during midmorning hours. Power spectra and intracortical tomography were computed by LORETA in seven frequency bands and compared between groups. Spearman rank correlations were based on V-EEG and psychometric data. Statistical overall analysis by means of the omnibus significance test demonstrated significant (p < 0.01) differences between HD patients and controls. LORETA theta, alpha and beta power were decreased from early to late stages of the disease. Only advanced disease stages showed a significant increase in delta power, mainly in the right orbitofrontal cortex. Correlation analyses revealed that a decrease of alpha and theta power correlated significantly with increasing cognitive and motor decline. LORETA proved to be a sensitive instrument for detecting progressive electrophysiological changes in HD. Reduced alpha power seems to be a trait marker of HD, whereas increased prefrontal delta power seems to reflect worsening of the disease. Motor function and cognitive function deteriorate together with a decrease in alpha and theta power. This data set, so far the largest in HD research, helps to elucidate remaining uncertainties about electrophysiological abnormalities in HD.

Entities:  

Mesh:

Year:  2010        PMID: 21161261     DOI: 10.1007/s00415-010-5852-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  79 in total

1.  Discussing the capabilities of Laplacian Minimization.

Authors:  R G de Peralta Menendez; S L Andino
Journal:  Brain Topogr       Date:  2000       Impact factor: 3.020

2.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

3.  Topographic classification of EEG patterns in Huntington's disease.

Authors:  R Bellotti; F De Carlo; R Massafra; M de Tommaso; V Sciruicchio
Journal:  Neurol Clin Neurophysiol       Date:  2004-11-30

Review 4.  Nonparametric analysis of statistic images from functional mapping experiments.

Authors:  A P Holmes; R C Blair; J D Watson; I Ford
Journal:  J Cereb Blood Flow Metab       Date:  1996-01       Impact factor: 6.200

5.  Location of sources of evoked scalp potentials: corrections for skull and scalp thicknesses.

Authors:  J P Ary; S A Klein; D H Fender
Journal:  IEEE Trans Biomed Eng       Date:  1981-06       Impact factor: 4.538

6.  Computer analysis of EEG activity in dementia of the Alzheimer's type and Huntington's disease.

Authors:  L J Streletz; P F Reyes; M Zalewska; L Katz; R G Fariello
Journal:  Neurobiol Aging       Date:  1990 Jan-Feb       Impact factor: 4.673

7.  Abnormalities of the contingent negative variation in Huntington's disease: correlations with clinical features.

Authors:  Marina de Tommaso; Olimpia Difruscolo; Vittorio Sciruicchio; Nicola Specchio; Paolo Livrea
Journal:  J Neurol Sci       Date:  2007-02-14       Impact factor: 3.181

8.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Quantitative EEG and dynamic susceptibility contrast MRI in Alzheimer's disease: a correlative study.

Authors:  Donatella Mattia; Fabio Babiloni; Andrea Romigi; Febo Cincotti; Luigi Bianchi; Francesca Sperli; Fabio Placidi; Alessandro Bozzao; Patrizia Giacomini; Roberto Floris; Maria Grazia Marciani
Journal:  Clin Neurophysiol       Date:  2003-07       Impact factor: 3.708

10.  Reduced regional cerebral blood flow in Huntington's disease studied by SPECT.

Authors:  S G Hasselbalch; G Oberg; S A Sørensen; A R Andersen; G Waldemar; J F Schmidt; K Fenger; O B Paulson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

View more
  9 in total

1.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

Review 2.  Neuronal Network Oscillations in Neurodegenerative Diseases.

Authors:  Volker Nimmrich; Andreas Draguhn; Nikolai Axmacher
Journal:  Neuromolecular Med       Date:  2015-04-29       Impact factor: 3.843

3.  Changes in brain activity with tominersen in early-manifest Huntington's disease.

Authors:  D J Hawellek; P Garces; A H Meghdadi; S Waninger; A Smith; M Manchester; S A Schobel; J F Hipp
Journal:  Brain Commun       Date:  2022-06-09

4.  Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.

Authors:  George V Rebec
Journal:  Antioxid Redox Signal       Date:  2013-06-19       Impact factor: 8.401

5.  Acute Sleep Deprivation Induces a Local Brain Transfer Information Increase in the Frontal Cortex in a Widespread Decrease Context.

Authors:  Joan F Alonso; Sergio Romero; Miguel A Mañanas; Marta Alcalá; Rosa M Antonijoan; Sandra Giménez
Journal:  Sensors (Basel)       Date:  2016-04-14       Impact factor: 3.576

Review 6.  Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntington's Disease: Are They Fit-for-Purpose for Treatment Development?

Authors:  Michael K Leuchter; Elissa J Donzis; Carlos Cepeda; Aimee M Hunter; Ana María Estrada-Sánchez; Ian A Cook; Michael S Levine; Andrew F Leuchter
Journal:  Front Neurol       Date:  2017-03-30       Impact factor: 4.003

7.  EEG Functional Connectivity and Cognitive Variables in Premanifest and Manifest Huntington's Disease: EEG Low-Resolution Brain Electromagnetic Tomography (LORETA) Study.

Authors:  Marianna Delussi; Virgilio Nazzaro; Katia Ricci; Marina de Tommaso
Journal:  Front Physiol       Date:  2020-12-17       Impact factor: 4.566

8.  The focused quantitative EEG bio-marker in studying childhood atrophic encephalopathy.

Authors:  Sungura Richard; Shirima Gabriel; Spitsbergen John; Mpolya Emmanuel; Vianney John-Mary
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

9.  EEG may serve as a biomarker in Huntington's disease using machine learning automatic classification.

Authors:  Omar F F Odish; Kristinn Johnsen; Paul van Someren; Raymund A C Roos; J Gert van Dijk
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.